Assessment of technical errors and validation processes in economic models submitted by the company for NICE technology appraisals

3 July 2020 - Economic models play a central role in the decision-making process of NICE.  ...

Read more →

Choosing a time horizon in cost and cost-effectiveness analyses

21 February 2019 - When designing a comparative outcomes or a cost-effectiveness analysis, the time horizon defining the duration of time ...

Read more →

Using evidence from randomised controlled trials in economic models: what information is relevant and is there a minimum amount of sample data required to make decisions?

21 September 2018 - Evidence from randomised controlled trials is used to support regulatory approval and reimbursement decisions.  ...

Read more →

Challenges and methodologies in using progression free survival as a surrogate for overall survival in oncology

11 July 2018 - A primary outcome in oncology trials is overall survival. However, to estimate overall survival accurately requires ...

Read more →

Takeda pioneers NICE’s new service for economic model review

7 June 2018 - NICE Scientific Advice (NSA) launched a new health economic model review service, PRIMA, in December 2017 and ...

Read more →